One in 10 babies is born too soon
Preterm birth, defined as delivery before 37 weeks of gestation, affects about 1 in 10 pregnancies and remains a significant maternal and neonatal public health concern.5 The short-and long-term impacts on infants and families can be profound, with significant clinical and economic consequences. Until recently, accurately identifying which pregnancies are at risk has been difficult.
Standard clinical risk assessment models based on medical history, demographic factors, and obstetric history capture only a fraction of preterm birth cases.
Determine your patient’s risk of spontaneous preterm birth, even if she lacks evident risk factors
The PreTRM® Test, a maternal blood biomarker test, helps identify which asymptomatic, singleton pregnancies are at higher or not higher risk for spontaneous preterm birth. Results are reported as either a higher or not higher risk, to guide more proactive care, prioritizing resources where they’re needed and enabling earlier preventive care discussions.
Improving Outcomes in Preterm Birth
Learn how the PreTRM® Test helps identify risk for spontaneous preterm birth — even in women without known risk factors. Maternal-fetal medicine specialist Dr. Brian Iriye and OB-GYN Dr. Tiffany Inglis share key insights from the landmark PRIME study and explain how early risk assessment, combined with commonly used preventive interventions can support healthier pregnancies and improve outcomes for moms and babies.
Appropriate Patients for the PreTRM® Test
The PreTRM® Test is intended for asymptomatic women with a singleton pregnancy and is performed via a single maternal blood sample collected between 180/7 and 206/7 weeks of gestation paired with personal history questions about a mom’s prior pregnancies and clinical factors.4,6 It is not for use in multiple pregnancies, suspected fetal anomalies, or women receiving progesterone therapy after the first trimester.6 PreTRM allows you to confidently triage care and focus attention where it’s most needed.
Request coverage of the PreTRM® Test for your patients
Coverage for the PreTRM Test is expanding and your voice makes a difference. Download the template letter and send it to a health plan or state Medicaid agency — clinician advocacy is the most effective way to convince a payer of the need for coverage.
Provider Portal
Offer the PreTRM® Test at Your Practice
References
- Osterman, MJK, et al. Births: Final Data for 2020. Division of Vital Statistics, National Center for Health Statistics, U.S. Centers for Disease Control and Prevention. (February 2022). Available at https://www.cdc.gov/nchs/nvss/births.htm
- Iams, JD. Clinical Practice. Prevention of preterm parturition. N Engl J Med. 2014;370:254-61.
- Burchard, J., et al. Better Estimation of Spontaneous Preterm Birth Prediction Performance through Improved Gestational Age Dating. J. Clin. Med. 2022, 11, 2885. https://doi.org/10.3390/jcm11102885
- Petrini JR, et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol. 2005;105:267-72.
- Hassan SS, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38:18-31.
- Considerations for use: The PreTRM Test for Risk Management predicts the risk of spontaneous preterm birth (before 37 weeks) in asymptomatic women (no signs or symptoms of preterm labor with intact membranes) ≥18 years old with a singleton pregnancy. The PreTRM Test is performed via a single blood draw between 18wk – 20wk/6d (126 – 146 days) gestation. It is not intended for use in women who have a multiple pregnancy, have a known or suspected fetal anomaly, or are on any form of progesterone therapy after the first trimester. If the PreTRM Test was ordered for a patient outside of intended use for this test, caution should be exercised when interpreting the personalized risk results.